<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-22057" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Gardnerella Vaginalis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kairys</surname>
            <given-names>Norah</given-names>
          </name>
          <aff>Temple University Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Carlson</surname>
            <given-names>Karen</given-names>
          </name>
          <aff>University of Nebraska Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Garg</surname>
            <given-names>Manish</given-names>
          </name>
          <aff>Temple University Hospital</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Norah Kairys declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Karen Carlson declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Manish Garg declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>12</day>
          <month>11</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-22057.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p><italic toggle="yes">Gardnerella vaginalis</italic> is a predominant anaerobic bacterium responsible for causing bacterial vaginosis (BV) in women. Although&#x000a0;<italic toggle="yes">G vaginalis</italic>&#x000a0;is a natural component of the normal vaginal flora, an excessive proliferation of this bacterium can lead to BV, the primary cause of&#x000a0;abnormal vaginal discharge or vaginitis.&#x000a0;<italic toggle="yes">Gardnerella</italic> infection poses distinctive challenges due to its far-reaching implications on women's reproductive health, susceptibility to sexually transmitted diseases, and potential to give rise to complications during pregnancy.&#x000a0;This activity comprehensively reviews the evaluation and treatment of BV caused by an overgrowth of&#x000a0;<italic toggle="yes">G vaginalis</italic>. Furthermore, this activity elucidates the crucial role of the interprofessional team in effectively treating patients afflicted by this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Differentiate between Gardnerella vaginalis&#x02013;associated bacterial vaginosis and other vaginal infections based on clinical presentation and laboratory findings.</p></list-item><list-item><p>Implement evidence-based treatment strategies for bacterial vaginosis, considering the role of Gardnerella vaginalis and other implicated microorganisms.</p></list-item><list-item><p>Apply knowledge of the microbiology and pathophysiology of Gardnerella vaginalis to educate patients about Gardnerella infections and recurrence, as well as guide treatment decisions.</p></list-item><list-item><p>Collaborate with the interprofessional team to share insights and optimize the diagnosis and management of initial and recurrent Gardnerella infections.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22057&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22057">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-22057.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p><italic toggle="yes">Gardnerella vaginalis</italic>&#x000a0;is a predominant anaerobic bacterium that is a natural component of the normal vaginal&#x000a0;flora.<xref ref-type="bibr" rid="article-22057.r1">[1]</xref>&#x000a0;<italic toggle="yes">Gardnerella</italic> was named after Hermann L. Gardner, the scientist who discovered the bacterium in 1955.&#x000a0;Normally, the&#x000a0;<italic toggle="yes">Lactobacillus&#x000a0;species</italic> predominates the vaginal flora.&#x000a0;However,&#x000a0;when&#x000a0;organisms such as <italic toggle="yes">Gardnerella</italic>&#x000a0;overgrow and assume dominance, this imbalance results in bacterial vaginosis (BV).&#x000a0;</p>
        <p>BV is a condition that causes abnormal vaginal discharge&#x000a0;and involves a polymicrobial overgrowth of anaerobic bacteria within the vaginal environment.&#x000a0;BV is associated with infertility, preterm birth, postpartum endometritis, pelvic inflammatory disease, and an increased risk of acquiring human immunodeficiency virus (HIV) and other sexually transmitted infections (STIs).<xref ref-type="bibr" rid="article-22057.r1">[1]</xref><xref ref-type="bibr" rid="article-22057.r2">[2]</xref></p>
      </sec>
      <sec id="article-22057.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The exact etiology of&#x000a0;BV resulting from the proliferation of <italic toggle="yes">Gardnerella</italic> bacteria remains unknown.<xref ref-type="bibr" rid="article-22057.r3">[3]</xref>&#x000a0;Although <italic toggle="yes">G vaginalis</italic> is not considered contagious, the extent of its transmissibility remains incompletely understood.<xref ref-type="bibr" rid="article-22057.r4">[4]</xref> The transmission of this bacterium among individuals through sexual intercourse could disrupt the natural bacterial balance within the vagina. Such an imbalance could lead to the onset of BV.<xref ref-type="bibr" rid="article-22057.r4">[4]</xref>&#x000a0;In most cases, BV is caused by a reduced population of normal&#x000a0;<italic toggle="yes">Lactobacillus species</italic> that produce lactic acid and hydrogen peroxide. This decrease paves the way for an excessive growth of opportunistic, anaerobic bacteria, including <italic toggle="yes">G vaginalis</italic>.<xref ref-type="bibr" rid="article-22057.r4">[4]</xref></p>
        <p>In the past, BV was referred to as G vaginitis due to the belief that this bacterium was responsible for the condition.<xref ref-type="bibr" rid="article-22057.r1">[1]</xref>&#x000a0;However, the term BV, which is more contemporary, effectively highlights that various naturally occurring anaerobic bacteria in the vaginal ecosystem might undergo excessive proliferation.&#x000a0;This imbalance in the vaginal environment serves as the root cause of BV.</p>
        <p>Research has identified <italic toggle="yes">G vaginalis</italic> in the vaginal tracts of as many as 50% of asymptomatic women. This observation has led to the assumption that <italic toggle="yes">Gardnerella</italic> could potentially be a component of the normal vaginal flora.&#x000a0;Various factors that might contribute to the development&#x000a0;of BV include frequent baths, douching, smoking, engaging in multiple sexual partners, using over-the-counter intravaginal hygiene products, experiencing severe stress, and increased frequency of sexual intercourse. BV might also be more prevalent among women who do not frequently change their underwear.<xref ref-type="bibr" rid="article-22057.r5">[5]</xref></p>
      </sec>
      <sec id="article-22057.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>BV is the most prevalent vaginal infection in women of reproductive age, with estimated occurrences ranging from 5% to 70%.<xref ref-type="bibr" rid="article-22057.r6">[6]</xref> The prevalence of BV among women fluctuates from 20% to 60% across various countries. In the United States, BV rates are approximately 30%.<xref ref-type="bibr" rid="article-22057.r7">[7]</xref>&#x000a0;BV rates are lowest in Australia, New Zealand, and&#x000a0;Western Europe.<xref ref-type="bibr" rid="article-22057.r3">[3]</xref> BV exhibits a higher prevalence among black women compared to white women.</p>
        <p>In addition, it is more frequently encountered in women with multiple sexual partners.<xref ref-type="bibr" rid="article-22057.r5">[5]</xref>&#x000a0;<italic toggle="yes">Gardnerella</italic>&#x000a0;has consistently been identified as a significant pathogen in BV, indicating a notable prevalence of <italic toggle="yes">Gardnerella</italic>&#x000a0;in these populations.<xref ref-type="bibr" rid="article-22057.r6">[6]</xref></p>
      </sec>
      <sec id="article-22057.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Although the exact pathophysiology is&#x000a0;uncertain, the prevailing notion is that most BV infections initiate with a biofilm formed by <italic toggle="yes">G vaginalis</italic>. This biofilm subsequently provides a conducive environment for the proliferation of other opportunistic bacteria.<xref ref-type="bibr" rid="article-22057.r8">[8]</xref>&#x000a0;<italic toggle="yes">G vaginalis</italic> produces vaginolysin,&#x000a0;a pore-forming toxin affecting&#x000a0;human cells.&#x000a0;Vaginolysin is a cholesterol-dependent cytolysin that initiates complex signaling cascades that trigger target cell lysis and&#x000a0;enhance&#x000a0;<italic toggle="yes">Gardnerella&#x02019;s</italic> virulence. Furthermore, this bacterium is often accompanied by protease and sialidase enzyme activities.&#x000a0;</p>
        <p><italic toggle="yes">Gardnerella</italic> has the necessary virulence factors that facilitate its adherence to host epithelial cells, enabling it to compete with Lactobacillus for dominance within the vaginal environment effectively. The symptoms of BV are believed to arise from the proliferation of usually dormant vaginal anaerobes that establish symbiotic relationships with <italic toggle="yes">Gardnerella</italic>.<xref ref-type="bibr" rid="article-22057.r9">[9]</xref></p>
      </sec>
      <sec id="article-22057.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p><italic toggle="yes">G vaginalis</italic> is a coccobacillus that lacks spore formation and motility.<xref ref-type="bibr" rid="article-22057.r4">[4]</xref>&#x000a0;This bacterium can be cultivated to form small, circular, gray colonies on both&#x000a0;chocolate and human blood bilayer agar media with Tween 80 (HBT medium)&#x000a0;agar.&#x000a0;A selective medium for <italic toggle="yes">Gardnerella</italic> is colistin-oxolinic acid blood sugar. Although&#x000a0;<italic toggle="yes">Gardnerella</italic> has a thin, gram-positive cell wall, it is regarded as gram-variable as its appearance can oscillate between gram-positive and gram-negative due to the fluctuating visibility of its thin cell wall.<xref ref-type="bibr" rid="article-22057.r10">[10]</xref></p>
        <p>For approximately 40 years, <italic toggle="yes">G vaginalis</italic> stood as the&#x000a0;only recognized species within its <italic toggle="yes">Gardnerella</italic> genus. More recently, as many as 13 new species have been identified, including <italic toggle="yes">G leopoldii, G piotii,</italic>&#x000a0;and&#x000a0;<italic toggle="yes">G swidsinskii.</italic><xref ref-type="bibr" rid="article-22057.r2">[2]</xref></p>
      </sec>
      <sec id="article-22057.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Women harboring <italic toggle="yes">G vaginalis</italic> are typically asymptomatic unless an imbalance occurs between <italic toggle="yes">Gardnerella</italic> and <italic toggle="yes">Lactobacillus</italic> populations.<xref ref-type="bibr" rid="article-22057.r11">[11]</xref>&#x000a0;Approximately 50% of women affected by BV experience symptoms.<xref ref-type="bibr" rid="article-22057.r3">[3]</xref> Symptomatic women&#x000a0;often report a malodorous vaginal discharge that intensifies following sexual intercourse. Itching may also be a concurrent complaint.&#x000a0;</p>
      </sec>
      <sec id="article-22057.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>BV is diagnosed using either Amsel criteria or the Nugent score. Amsel criteria are commonly used in the clinical setting and require the fulfillment of at least 3 out of 4 specified criteria.&#x000a0;</p>
        <p>
<bold>Amsel Criteria</bold>
</p>
        <p>Amsel Criteria include the following indicators that collectively aid in the accurate assessment of the condition:</p>
        <list list-type="bullet">
          <list-item>
            <p>Homogenous, thin, grayish-white vaginal discharge that coats the vaginal walls evenly</p>
          </list-item>
          <list-item>
            <p>Detection of &#x02265;20% clue cells on a wet mount</p>
          </list-item>
          <list-item>
            <p>Vaginal pH &#x02265;4.5</p>
          </list-item>
          <list-item>
            <p>Positive whiff test</p>
          </list-item>
        </list>
        <p>Clue cells are vaginal epithelial cells that are covered with rod-shaped bacteria (see <bold>Image.</bold> Clue Cells).<xref ref-type="bibr" rid="article-22057.r9">[9]</xref>&#x000a0;A drop of sodium chloride solution is placed on the wet-mount slide containing the vaginal specimen, and upon microscopic examination, this technique reveals the distinctive clue cells. The whiff test is performed by adding a small amount of potassium hydroxide onto the microscopic slide containing the vaginal discharge. The positive whiff test is determined when a distinctive fishy odor becomes perceptible.<xref ref-type="bibr" rid="article-22057.r12">[12]</xref>&#x000a0;</p>
        <p>The Nugent scoring system employs a microscopic examination and gram-stain technique to evaluate the presence of vaginal bacteria, assigning a numerical score ranging from 0 to 10. A higher score indicates a more significant presence of bacteria associated with BV.<xref ref-type="bibr" rid="article-22057.r13">[13]</xref> Nugent score is primarily utilized within the realm of research.</p>
        <p>Generally, point-of-care tests are not commonly utilized in clinical settings due to their high cost. Instead, clinical practitioners often rely on commercial molecular diagnostic assays for assessment. These tests enable the quantification of bacteria and exhibit a sensitivity ranging from 90.5% to 96.7% and a specificity&#x000a0;of 85.8% to 95%.<xref ref-type="bibr" rid="article-22057.r5">[5]</xref> Since introducing the rapid identification method in 1982, isolating 91.4% of <italic toggle="yes">Gardnerella</italic> strains using a micromethod involving starch, raffinose fermentation, and hippurate hydrolysis has become possible.<xref ref-type="bibr" rid="article-22057.r14">[14]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-22057.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Treatment is not necessary for asymptomatic <italic toggle="yes">Gardnerella</italic> colonization. Currently, insufficient evidence&#x000a0;supports&#x000a0;the notion that treating asymptomatic BV reduces adverse patient outcomes.<xref ref-type="bibr" rid="article-22057.r13">[13]</xref> Approximately 30% of BV cases are known to resolve without treatment.<xref ref-type="bibr" rid="article-22057.r1">[1]</xref> However, if a patient experiences distress due to the symptoms of BV, it is recommended to pursue treatment using either oral or vaginal medication, as detailed below.</p>
        <p>In 2017, secnidazole was approved by the U.S. Food and Drug Administration (FDA) for single-dose oral treatment for BV.<xref ref-type="bibr" rid="article-22057.r13">[13]</xref>&#x000a0;Although secnidazole,&#x000a0;a next-generation 5-nitroimidazole, has a longstanding history of use in treating both parasitic and bacterial infections, it has recently been approved by the FDA for BV treatment in the United States.<xref ref-type="bibr" rid="article-22057.r15">[15]</xref>&#x000a0;</p>
        <p>Initial treatment for BV demonstrates notable efficacy, as cure rates within 1 month typically range from 80% to 90%.<xref ref-type="bibr" rid="article-22057.r3">[3]</xref>&#x000a0;Unfortunately, recurrence may occur in as many as 80% of women within 9 months following initial treatment.<xref ref-type="bibr" rid="article-22057.r1">[1]</xref><xref ref-type="bibr" rid="article-22057.r16">[16]</xref> If a patient experiences recurrent symptoms, a second course of antibiotics is generally prescribed.<xref ref-type="bibr" rid="article-22057.r1">[1]</xref>&#x000a0;A Cochrane review conducted in 2009 yielded tentative yet inconclusive evidence regarding the use of probiotics for treating and preventing BV.<xref ref-type="bibr" rid="article-22057.r17">[17]</xref>&#x000a0;Importantly, it is worth noting that there is no universally established, strict definition for recurrent BV.</p>
        <p><bold>Treatment Regimens</bold>
<bold>for BV</bold></p>
        <p>The treatment regimens used to manage the condition are listed below when treating BV.</p>
        <p><bold>Metronidazole:</bold> This medication is administered orally at 500 mg twice daily for 7 days.</p>
        <p><bold>Metronidazole intravaginal gel:</bold>&#x000a0;This gel is used at a 0.75% strength, and the recommended regimen involves applying 5 g of the gel intravaginally once daily for 5 days.</p>
        <p><bold>Clindamycin intravaginal cream:</bold>&#x000a0;This cream is used&#x000a0;at a 2% strength, and the recommended dosage involves applying 5 g of the cream nightly for 7 days.</p>
        <p><bold>Alternate Treatment Regimens</bold>
<bold>for BV</bold></p>
        <p>The alternative regimens for addressing BV are listed below.</p>
        <p><bold>Clindamycin intravaginal ovules:</bold>&#x000a0;This medication is administered as 100 mg ovules, taken intravaginally on a nightly basis for 3 days.</p>
        <p><bold>Clindamycin oral tablets:</bold>&#x000a0;This medication&#x000a0;is prescribed at 300 mg, taken orally twice daily for 7 days.</p>
        <p><bold>Tinidazole:</bold>&#x000a0;This medication can be taken orally either as a 5-day course at a dosage of 1 g daily or a shorter 2-day treatment at 2 g daily.</p>
        <p><bold>Secnidazole oral granules:</bold>&#x000a0;This medication&#x000a0;is administered as a single dose of 2 g of oral granules.</p>
      </sec>
      <sec id="article-22057.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis for BV&#x000a0;includes atrophic vaginitis, candidiasis, cervicitis, chlamydia, desquamative inflammatory vaginitis, gonorrhea, herpes simplex, and trichomoniasis.</p>
        <p>A thorough pelvic examination can effectively refine the differential diagnosis and&#x000a0;exclude other similar conditions, such as vaginal candidiasis, trichomonas vaginitis, or herpes simplex virus. A speculum exam aids in the identification of cervicitis, while a wet mount of the vaginal discharge assists in discerning the presence of candidiasis or trichomoniasis.<xref ref-type="bibr" rid="article-22057.r1">[1]</xref> Furthermore, additional cervical swab cultures can be dispatched to assess for chlamydia and gonorrhea.<xref ref-type="bibr" rid="article-22057.r18">[18]</xref></p>
      </sec>
      <sec id="article-22057.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Most uncomplicated cases of BV resolve with treatment. However, recurrences are not uncommon due to the frequent failure of antibiotic treatment to restore the vagina to its typical <italic toggle="yes">Lactobacillus</italic>-dominated&#x000a0;state. The biofilms of <italic toggle="yes">Gardnerella</italic> bacteria create a shield that helps prevent metronidazole from penetrating.<xref ref-type="bibr" rid="article-22057.r7">[7]</xref> Within 3 months following treatment, approximately 80% of women may experience a recurrence of BV. In the past decade, there has been a growing number of reports regarding BV strains that are resistant to conventional treatments and do not respond to them.</p>
        <p>In a recent randomized controlled trial, a powder containing the naturally occurring live strain <italic toggle="yes">Lactobacillus crispatus</italic> CTV-05 was used. Following metronidazole treatment, women utilized the intravaginal powder to reduce the recurrence of BV. The regimen involved using the powder 4 times daily during the first week, followed by twice-weekly use&#x000a0;for 10 weeks. The use of lactobacillus&#x000a0;powder after BV treatment with metronidazole significantly lowered the recurrence rate of BV up to 24 weeks after the treatment. Notably, this approach has not yet received FDA approval.<xref ref-type="bibr" rid="article-22057.r19">[19]</xref> Several alternative vaginal products are currently under investigation to enhance BV recurrence rates.</p>
        <p>BV has been associated with an increased risk of contracting STIs, including gonorrhea, chlamydia, trichomonas, herpes, human papillomavirus (HPV), and HIV. As <italic toggle="yes">Gardnerella</italic> damages the vaginal epithelium, it concurrently elevates the risk of HPV infection.<xref ref-type="bibr" rid="article-22057.r3">[3]</xref>&#x000a0;In addition, BV may contribute to tubal infertility and difficulties in conceiving with assisted reproductive techniques, but a causal relationship has not been established.<xref ref-type="bibr" rid="article-22057.r13">[13]</xref> The concept of treating heterosexual partners with antibiotics as a means to prevent recurrent BV is still under investigation, but it is not currently recommended as a routine strategy.<xref ref-type="bibr" rid="article-22057.r20">[20]</xref></p>
        <p>Intravaginal boric acid has also been recommended for managing recurrent BV. Although this regimen lacks FDA approval, the existing evidence indicates the safety of intravaginal boric acid usage in non-pregnant women. The recommended dosage of intravaginal boric acid for women is 600 mg, administered intravaginally twice weekly to prevent BV. The use of boric acid vaginal suppositories should be avoided during pregnancy, and it should not be taken orally.<xref ref-type="bibr" rid="article-22057.r20">[20]</xref></p>
        <p>According to the Centers for Disease Control and Prevention (CDC), multiple recurrences of BV can be managed using any 1 of the following treatment regimens:</p>
        <list list-type="bullet">
          <list-item>
            <p>Metronidazole gel 0.75% or metronidazole vaginal suppository 750 mg administered twice weekly for over 3 months.</p>
          </list-item>
          <list-item>
            <p>An oral nitroimidazole course comprising 500 mg metronidazole or tinidazole, taken twice daily for 7 days, followed by 600 mg intravaginal boric acid, administered daily for 21 days, and ongoing suppressive treatment with 0.75% metronidazole gel, applied twice weekly for 4 to 6 months.</p>
          </list-item>
          <list-item>
            <p>A monthly regimen involving oral administration of 2 g metronidazole taken concurrently with 150 mg oral fluconazole.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22057.s12" sec-type="Complications">
        <title>Complications</title>
        <p>The complications associated with BV are listed below.</p>
        <list list-type="bullet">
          <list-item>
            <p>Increased risk of endometritis and salpingitis.</p>
          </list-item>
          <list-item>
            <p>Elevated risk of postsurgical infections.</p>
          </list-item>
          <list-item>
            <p>Adverse pregnancy outcomes include premature labor, premature rupture of membranes, and postpartum endometritis.</p>
          </list-item>
          <list-item>
            <p>Development of pelvic inflammatory disease.</p>
          </list-item>
          <list-item>
            <p>Possibility of neonatal meningitis.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22057.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Providing patient education about <italic toggle="yes">Gardnerella</italic> can facilitate the identification of symptoms and subsequently enable timely treatment to mitigate potential complications associated with BV. Although the exact cause of the increased pH and bacterial overgrowth leading to BV remains incompletely understood, there are preventive measures that women can adopt to minimize the overgrowth of&#x000a0;<italic toggle="yes">G vaginalis</italic>. Healthcare providers should offer comprehensive education to women regarding the risk factors associated with BV, which encompass, but are not limited to, engaging in multiple sexual partners, douching, lack of condom usage, smoking, and having female sexual partners. By reducing these risks, a resultant decrease in BV incidence could potentially contribute to lowering the acquisition of other STIs and mitigating complications that may arise from&#x000a0;<italic toggle="yes">G vaginalis</italic> overgrowth.</p>
      </sec>
      <sec id="article-22057.s14" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Untreated BV can elevate the risk of complications during pregnancy&#x000a0;and increase susceptibility to STIs, including HIV.<xref ref-type="bibr" rid="article-22057.r18">[18]</xref> Data also indicate an association between BV and both tubal factor infertility and pelvic inflammatory disease. During pregnancy, BV has been associated with an increased risk of premature birth, miscarriage, chorioamnionitis, premature rupture of membranes, and postpartum endometritis.<xref ref-type="bibr" rid="article-22057.r21">[21]</xref> However, despite these associations, routine screening for BV during pregnancy is not recommended.&#x000a0;</p>
      </sec>
      <sec id="article-22057.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p><italic toggle="yes">Gardnerella</italic> is a common genital tract&#x000a0;overgrowth often encountered by emergency department physicians, nurse practitioners, family medicine clinicians, internists, and gynecologists. BV significantly diminishes the quality of life for women affected by it.<xref ref-type="bibr" rid="article-22057.r22">[22]</xref>&#x000a0;Asymptomatic&#x000a0;<italic toggle="yes">Gardnerella</italic>&#x000a0;colonization does not necessitate treatment, as nearly 30% of cases resolve spontaneously. Physicians, advanced care practitioners, and nurses must know this caveat to prevent unnecessary antibiotic overtreatment. While&#x000a0;all symptomatic patients require treatment, it is noteworthy that recurrences are prevalent even after the initial cure. Although BV is not classified as an STI, healthcare professionals are responsible for educating patients about the significance of practicing safe sex, avoiding multiple sexual partners, and utilizing barrier protection methods. The enhancement of patient safety and improvement in patient outcomes can be achieved through interprofessional communication and collaboration.&#x000a0;</p>
        <p>Untreated BV can increase the risk of pregnancy complications and STIs, including HIV.<xref ref-type="bibr" rid="article-22057.r18">[18]</xref>&#x000a0;Data also suggest an association between BV and tubal factor infertility and pelvic inflammatory disease.<xref ref-type="bibr" rid="article-22057.r21">[21]</xref> The recurrence of BV is distressing, as it has been linked to unfavorable social, emotional, and sexual impacts. BV maintains its economic strain on the healthcare system, necessitating multiple clinic visits and recurrent antibiotic utilization for patients.<xref ref-type="bibr" rid="article-22057.r19">[19]</xref></p>
      </sec>
      <sec id="article-22057.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22057&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22057">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/womens-health/gardnerella-vaginalis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=22057">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/22057/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=22057">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-22057.s17">
        <fig id="article-22057.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Clue Cells Image courtesy S Bhimji, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="clue__cells" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-22057.s18">
        <title>References</title>
        <ref id="article-22057.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hartmann</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>[Gardnerella vaginalis infection. Clinical aspects, diagnosis and therapy].</article-title>
            <source>Urologe A</source>
            <year>1987</year>
            <month>Sep</month>
            <volume>26</volume>
            <issue>5</issue>
            <fpage>252</fpage>
            <page-range>252-5</page-range>
            <pub-id pub-id-type="pmid">3318083</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22057.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Castro</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jefferson</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Cerca</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Genetic Heterogeneity and Taxonomic Diversity among Gardnerella Species.</article-title>
            <source>Trends Microbiol</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>28</volume>
            <issue>3</issue>
            <fpage>202</fpage>
            <page-range>202-211</page-range>
            <pub-id pub-id-type="pmid">31699644</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22057.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coudray</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Madhivanan</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Bacterial vaginosis-A brief synopsis of the literature.</article-title>
            <source>Eur J Obstet Gynecol Reprod Biol</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>245</volume>
            <fpage>143</fpage>
            <page-range>143-148</page-range>
            <pub-id pub-id-type="pmid">31901667</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22057.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schwebke</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Muzny</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Josey</surname>
                <given-names>WE</given-names>
              </name>
            </person-group>
            <article-title>Role of Gardnerella vaginalis in the pathogenesis of bacterial vaginosis: a conceptual model.</article-title>
            <source>J Infect Dis</source>
            <year>2014</year>
            <month>Aug</month>
            <day>01</day>
            <volume>210</volume>
            <issue>3</issue>
            <fpage>338</fpage>
            <page-range>338-43</page-range>
            <pub-id pub-id-type="pmid">24511102</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22057.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abou Chacra</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Fenollar</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Diop</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Bacterial Vaginosis: What Do We Currently Know?</article-title>
            <source>Front Cell Infect Microbiol</source>
            <year>2021</year>
            <volume>11</volume>
            <fpage>672429</fpage>
            <pub-id pub-id-type="pmid">35118003</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22057.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Janulaitiene</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Paliulyte</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Grinceviciene</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zakareviciene</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vladisauskiene</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Marcinkute</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pleckaityte</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Prevalence and distribution of Gardnerella vaginalis subgroups in women with and without bacterial vaginosis.</article-title>
            <source>BMC Infect Dis</source>
            <year>2017</year>
            <month>Jun</month>
            <day>05</day>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>394</fpage>
            <pub-id pub-id-type="pmid">28583109</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22057.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gustin</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Thurman</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Chandra</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Schifanella</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Alcaide</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fichorova</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Doncel</surname>
                <given-names>GF</given-names>
              </name>
              <name>
                <surname>Gale</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Klatt</surname>
                <given-names>NR</given-names>
              </name>
            </person-group>
            <article-title>Recurrent bacterial vaginosis following metronidazole treatment is associated with microbiota richness at diagnosis.</article-title>
            <source>Am J Obstet Gynecol</source>
            <year>2022</year>
            <month>Feb</month>
            <volume>226</volume>
            <issue>2</issue>
            <fpage>225.e1</fpage>
            <page-range>225.e1-225.e15</page-range>
            <pub-id pub-id-type="pmid">34560047</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22057.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Machado</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cerca</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Influence of Biofilm Formation by Gardnerella vaginalis and Other Anaerobes on Bacterial Vaginosis.</article-title>
            <source>J Infect Dis</source>
            <year>2015</year>
            <month>Dec</month>
            <day>15</day>
            <volume>212</volume>
            <issue>12</issue>
            <fpage>1856</fpage>
            <page-range>1856-61</page-range>
            <pub-id pub-id-type="pmid">26080369</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22057.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baruah</surname>
                <given-names>FK</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Das</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hazarika</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Hussain</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Role of Gardnerella vaginalis as an etiological agent of bacterial vaginosis.</article-title>
            <source>Iran J Microbiol</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>6</volume>
            <issue>6</issue>
            <fpage>409</fpage>
            <page-range>409-14</page-range>
            <pub-id pub-id-type="pmid">25926959</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22057.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hardy</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Jespers</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Dahchour</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mwambarangwe</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Musengamana</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Vaneechoutte</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Crucitti</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Unravelling the Bacterial Vaginosis-Associated Biofilm: A Multiplex Gardnerella vaginalis and Atopobium vaginae Fluorescence In Situ Hybridization Assay Using Peptide Nucleic Acid Probes.</article-title>
            <source>PLoS One</source>
            <year>2015</year>
            <volume>10</volume>
            <issue>8</issue>
            <fpage>e0136658</fpage>
            <pub-id pub-id-type="pmid">26305575</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22057.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hartmann</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Elsner</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>[Gardnerella vaginalis infection--another sexually transmitted disease].</article-title>
            <source>Hautarzt</source>
            <year>1984</year>
            <month>Oct</month>
            <volume>35</volume>
            <issue>10</issue>
            <fpage>512</fpage>
            <page-range>512-6</page-range>
            <pub-id pub-id-type="pmid">6389437</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22057.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elsner</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hartmann</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Wecker</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>[Detection of Gardnerella vaginalis in the pathogen spectrum of sexually transmissible diseases in vulvovaginitis].</article-title>
            <source>Z Hautkr</source>
            <year>1985</year>
            <month>Nov</month>
            <day>01</day>
            <volume>60</volume>
            <issue>21</issue>
            <fpage>1655</fpage>
            <page-range>1655-62</page-range>
            <pub-id pub-id-type="pmid">3907172</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22057.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ravel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Moreno</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Sim&#x000f3;n</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Bacterial vaginosis and its association with infertility, endometritis, and pelvic inflammatory disease.</article-title>
            <source>Am J Obstet Gynecol</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>224</volume>
            <issue>3</issue>
            <fpage>251</fpage>
            <page-range>251-257</page-range>
            <pub-id pub-id-type="pmid">33091407</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22057.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Catlin</surname>
                <given-names>BW</given-names>
              </name>
            </person-group>
            <article-title>Gardnerella vaginalis: characteristics, clinical considerations, and controversies.</article-title>
            <source>Clin Microbiol Rev</source>
            <year>1992</year>
            <month>Jul</month>
            <volume>5</volume>
            <issue>3</issue>
            <fpage>213</fpage>
            <page-range>213-37</page-range>
            <pub-id pub-id-type="pmid">1498765</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22057.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Muzny</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Van Gerwen</surname>
                <given-names>OT</given-names>
              </name>
            </person-group>
            <article-title>Secnidazole for Trichomoniasis in Women and Men.</article-title>
            <source>Sex Med Rev</source>
            <year>2022</year>
            <month>Apr</month>
            <volume>10</volume>
            <issue>2</issue>
            <fpage>255</fpage>
            <page-range>255-262</page-range>
            <pub-id pub-id-type="pmid">35153156</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22057.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tosun</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Alpay Karao&#x0011f;lu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cift&#x000e7;i</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Buruk</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Aydin</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kili&#x000e7;</surname>
                <given-names>AO</given-names>
              </name>
              <name>
                <surname>Ert&#x000fc;rk</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>[Biotypes and antibiotic resistance patterns of Gardnerella vaginalis strains isolated from healthy women and women with bacterial vaginosis].</article-title>
            <source>Mikrobiyol Bul</source>
            <year>2007</year>
            <month>Jan</month>
            <volume>41</volume>
            <issue>1</issue>
            <fpage>21</fpage>
            <page-range>21-7</page-range>
            <pub-id pub-id-type="pmid">17427549</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22057.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nagaraja</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Antibiotic resistance of Gardnerella vaginalis in recurrent bacterial vaginosis.</article-title>
            <source>Indian J Med Microbiol</source>
            <year>2008</year>
            <season>Apr-Jun</season>
            <volume>26</volume>
            <issue>2</issue>
            <fpage>155</fpage>
            <page-range>155-7</page-range>
            <pub-id pub-id-type="pmid">18445953</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22057.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elsner</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hartmann</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Wecker</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Gardnerella vaginalis is associated with other sexually transmittable microorganisms in the male urethra.</article-title>
            <source>Zentralbl Bakteriol Mikrobiol Hyg A</source>
            <year>1988</year>
            <month>Jul</month>
            <volume>269</volume>
            <issue>1</issue>
            <fpage>56</fpage>
            <page-range>56-63</page-range>
            <pub-id pub-id-type="pmid">3140532</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22057.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cohen</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Wierzbicki</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>French</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Newmann</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Reno</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Powell</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Parks</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hemmerling</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Randomized Trial of Lactin-V to Prevent Recurrence of Bacterial Vaginosis.</article-title>
            <source>N Engl J Med</source>
            <year>2020</year>
            <month>May</month>
            <day>14</day>
            <volume>382</volume>
            <issue>20</issue>
            <fpage>1906</fpage>
            <page-range>1906-1915</page-range>
            <pub-id pub-id-type="pmid">32402161</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22057.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Plummer</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Vodstrcil</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Doyle</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Danielewski</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Murray</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Fehler</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fairley</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Bulach</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Garland</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Chow</surname>
                <given-names>EPF</given-names>
              </name>
              <name>
                <surname>Hocking</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Bradshaw</surname>
                <given-names>CS</given-names>
              </name>
            </person-group>
            <article-title>A Prospective, Open-Label Pilot Study of Concurrent Male Partner Treatment for Bacterial Vaginosis.</article-title>
            <source>mBio</source>
            <year>2021</year>
            <month>Oct</month>
            <day>26</day>
            <volume>12</volume>
            <issue>5</issue>
            <fpage>e0232321</fpage>
            <pub-id pub-id-type="pmid">34663095</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22057.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kasprowicz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bia&#x00142;ecka</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>[Gardnerella vaginalis in infections of reproductive organs].</article-title>
            <source>Med Dosw Mikrobiol</source>
            <year>1993</year>
            <volume>45</volume>
            <issue>2</issue>
            <fpage>199</fpage>
            <page-range>199-203</page-range>
            <pub-id pub-id-type="pmid">8309297</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22057.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chow</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wooten</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Annepally</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Burke</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Edi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>Impact of (recurrent) bacterial vaginosis on quality of life and the need for accessible alternative treatments.</article-title>
            <source>BMC Womens Health</source>
            <year>2023</year>
            <month>Mar</month>
            <day>18</day>
            <volume>23</volume>
            <issue>1</issue>
            <fpage>112</fpage>
            <pub-id pub-id-type="pmid">36934289</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
